E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

European Journal of Cancer

Volumn 37, Issue 17, 2001, Pages 2275-2282

  Ozawa, Y ^a   Sugi, N H ^a   Nagasu, T ^a   Owa, T ^a   Watanabe, T ^a   Koyanagi, N ^a   Yoshino, H ^a   Kitoh, K ^a   Yoshimatsu, K ^a  

^a EISAI CO LTD   (Japan)

Author keywords

E7070; G1 phase; Human tumour xenograft model; Sulphonamide

Indexed keywords

BLEOMYCIN; CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INDISULAM; IRINOTECAN; MITOMYCIN C; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL KILLING; CHRONOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA P 388; LUNG CARCINOMA; MOUSE; NONHUMAN; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; DRUG ADMINISTRATION SCHEDULE; FEMALE; G1 PHASE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034773165     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00275-1     Document Type: Article

References (31)

1. Nocel sulfonamides as potential, systemically active antitumor agents
2. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin
3. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors
4. Phase I study of E7010
5. A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors
6. Novel sulphonamide derivatives for the treatment of cancer
7. Discovery of novel antitumour sulfonamides targeting G1 phase of the cell cycle
8. G1 phase progression: Cycling on cue
9. Cell cycle regulation and apoptosis
10. Cancer cell cycles
11. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells
12. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation
13. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle
14. Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group
15. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
16. New colorimetric cytotoxicity assay for anticancer-drug screening
17. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
18. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
19. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study
20. CPT-11 in gastrointestinal cancer
21. The efficacy of intra-arterial infusion chemotherapy in patients with non-resectable liver metastasis from colorectal cancer - A randomized study comparing FAM versus FEM
22. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel
23. Effects of BMY25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells
24. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
25. Microarray-baced expression profiling of sulfonamide antitumor agents
26. Human tumor xenograft models in NCI drug development
27. Multiresistant phenotype of disease-oriented panels of humantumor cell lines used for anticancer drug screening
28. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines
29. A novel antitumor agent ER-35744, targeting G1 phase. III. Studies of mechanism of action
30. Functional analysis of G1 and G2 cell cycle checkpoints in cells of the NCI drug screen and relationship to p53 status
31. Biological characterization and oncogene expression in human colorectal carcinoma cell lines